It is very common for these biotechs to have a scary downturn right before a big move up.
So maybe that is what we are setting MNTA up for. The fund might have sold on the move up to 12 and will be buying back on weakness, who knows what their trading strategy is.
The important question seems to be, what is a good level to buy MNTA at this time?
Market Data 
Markets 
AI
